Evaluation of Sentinel Lymph Nodes in Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma (HNSCC) Clinical Trial

Official title:

A Ph 3, Prospective, Open-Label, Multicenter Study of Lymphoseek®-Identified Sentinel Lymph Nodes (SLNs) Relative to the Path Status of Non SLN in an Elective Neck Dissection in Cutaneous Head and Neck and Intraoral Squamous Cell Carcinoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00911326
• Other study ID #: NEO3-06
• Status: Terminated
• Phase: Phase 3
• First received: May 28, 2009
• Last updated: August 6, 2014
• Start date: May 2009
• Est. completion date: August 2013

Study information

• Verified date: August 2014
• Source: Navidea Biopharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the false negative rate (FNR) associated with Lymphoseek-identified sentinel lymph nodes (SLNs) relative to the pathological status of non-sentinel lymph nodes in elective neck dissection (END) in head & neck squamous cell carcinoma (HNSCC). NEO3-06 (this study) is a Phase 3 clinical trial designed to supplement NEO3-05, a completed Phase 3 clinical trial conducted in patients with breast cancer or melanoma. NEO3-05 was designed to establish Lymphoseek as an effective radio-diagnostic agent to be used in the intraoperative localization of lymph tissue (nodes) in the lymphatic pathway draining the primary site of a tumor.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 101
• Est. completion date: August 2013
• Est. primary completion date: August 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

Subjects meeting all of the following inclusion criteria by the end of the screening phase should be considered for admission to the study:

1. The patient has provided written informed consent with Health Insurance Portability and Accountability Act (HIPAA) authorization before participating in the study.

2. The patient has a diagnosis of primary squamous cell carcinoma of the head and neck either cutaneous or intra-oral that is anatomically located in: mucosal lip, buccal mucosa, lower alveolar ridge, upper alveolar ridge, retromolar gingiva (retromolar trigone), floor of the mouth, hard palette or oral (mobile) tongue, stage T1-T4a, N0, M0.

3. Clinical nodal staging (N0) has been confirmed by negative results from contrast CT scan or gadolinium-enhanced MRI or lateral and central neck ultrasound. PET scan cannot be used for this evaluation.

4. Imaging of the regional nodal basin has been performed within 30 days of the planned lymphadenectomy.

5. The patient is a candidate for surgical intervention, with intraoperative lymphatic mapping and END included in the surgical plan.

6. Patients with prior malignancy are allowed provided the patient meets the following criteria:

Underwent potentially curative therapy for all prior malignancies and is deemed low risk for recurrence; AND No malignancy for the past 5 years (except effectively treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix effectively treated with surgery alone, lobular carcinoma in situ of the ipsilateral or contralateral breast treated with surgery alone, or carcinoma of the mouth that is in situ or minimally invasive) and no evidence of recurrence.

7. The patient is at least 18 years of age at the time of consent.

8. The patient has an Eastern Cooperative Oncology Group (ECOG) status of Grade 0 - 2.

9. If the patient is a female, the patient has a confirmed negative pregnancy test within 72 hours priors to administration of Lymphoseek, OR has documentation of surgical sterilization, OR has documented evidence of postmenopausal status for at least 1 year.

Exclusion Criteria:

Patients meeting any of the following exclusion criteria at the end of the screening phase will not be enrolled in the study:

1. The patient has a diagnosis of squamous cell carcinoma of the head and neck in the following anatomical areas: non-mobile base of the tongue, oral pharynx, nasal pharynx, hypo-pharynx and larynx.

2. The patient is pregnant or lactating.

3. The patient has clinical or radiological evidence of metastatic cancer to the regional lymph nodes.

4. Patients with a history of neck dissection, or gross injury to the neck that would preclude reasonable surgical dissection for this study, or radiotherapy to the neck.

5. Patients who have had other nuclear imaging studies conducted within 15 days or consenting.

6. The patient is actively receiving systemic cytotoxic chemotherapy.

7. Patient is currently participating in another investigational drug study or participated within 30 days prior to consenting.

8. Patient is on immunosuppressive or anti-monocyte or immunomodulatory therapy.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Head and Neck Neoplasms
• Head and Neck Squamous Cell Carcinoma (HNSCC)

Intervention

Drug:
• Lymphoseek
Single injection of 50 micrograms Lymphoseek radiolabeled with either 0.5 mCi (for same day surgery) or 2.0 mCi (for next day surgery) of Tc 99m

Locations

Country	Name	City	State
United States	University of Michigan Medical Center	Ann Arbor	Michigan
United States	University of Alabama, Birmingham	Birminham	Alabama
United States	University of Missouri-Ellis Fischel Cancer Center	Columbia	Missouri
United States	The Ohio State University Comprehensive Cancer Center	Columbus	Ohio
United States	Duke University Medical Center	Durham	North Carolina
United States	MD Anderson	Houston	Texas
United States	University of Mississippi	Jackson	Mississippi
United States	University of Kansas Medical Center	Kansas City	Kansas
United States	Moores UCSD Cancer Center	La Jolla	California
United States	University of Miami, Sylvester Comprehensive Cancer Center	Miami	Florida
United States	University of Nebraska	Omaha	Nebraska
United States	Thomas Jefferson University	Philadelphia	Pennsylvania
United States	San Diego VA Hospital	San Diego	California

Sponsors (1)

Lead Sponsor	Collaborator
Navidea Biopharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	False Negative Rate (FNR)	The FNR is calculated as a percentage from the ratio of false negatives to the sum of true positives plus false negatives. The FNR point estimate was the observed rate and was made on a per-patient basis relative to patients with pathology-positive nodes.	Surgery after injection of Lymphoseek	No
Secondary	Negative Predictive Value (NPV)	The NPV is calculated as a percentage from the ratio of true negatives to the sum of true negatives plus false negatives. The NPV point estimate was the observed rate and was made on a per-patient basis relative to patients predicted to be pathology-negative.	Surgery after injection of Lymphoseek	No
Secondary	Overall Accuracy	The overall accuracy is calculated as a percentage from the ratio of (true positives + true negatives) / (true positives + false negatives + true negatives). The overall accuracy point estimate was the observed rate and was made on a per-patient basis relative to all patients in the intent-to-treat population.	Surgery after injection of Lymphoseek	No
Secondary	Lymph Node Detection Rate	The rate of the subjects for whom Lymphoseek identified at least 1 sentinel lymph node. The detection rate point estimate was the observed rate and was made on a per-patient basis relative to all patients in the intent-to-treat population.	Surgery after injection of Lymphoseek	No